rrx-001,regorafenib,irinotecan
epicentrx,bayer
[]
rocket science: we re at #gi23 this saturday in sanfran to share the positive results from our phase 2 #rocket study comparing the safety and efficacy of rrx-001 plus irinotecan vs. regorafenib in 34 patients with 3rd/4th line colorectal cancer. 
Innovation-driven drug and device company with a focus on minimally toxic therapies for cancer and chronic diseases. #cancertherapy #biotech